Return to site

Amniotic Products Market - Segmentation, Geographical Analysis & Major Key Players

The hospital & ASCs segment is expected to register the highest CAGR during the forecast period.
· Healthcare
Amniotic Products Market

According to the new market research report “Amniotic Products Market by Type [Amniotic Membranes (Cryopreserved Amniotic Membranes, Dehydrated Amniotic Membranes), Amniotic Suspensions], Application (Wound Care, Ophthalmology, Orthopedics), End User (Hospital, ASCs) – Global Forecast to 2025″ published by MarketsandMarkets™.
 

Revenue Growth Opportunities and Growth Drivers?
 

The Global Amniotic Membranes Market is projected to reach USD 1,095 million by 2025 from USD 748 million in 2020, at a CAGR of 7.9%
 

Growth Boosting Factors:

– Growth in the target patient population
– Rising incidence of burn injuries
– Awareness programs for wound care treatment and management
– Rise in venture capital investment and government funding
 

Recent Developments in Industry:
 

– In 2019, Smith & Nephew acquired Osiris Therapeutics, complementing the company’s advanced wound management unit by offering regenerative medicine products inclusive of skin, bone graft, and articular cartilage substitutes.
 

– In 2018, the US FDA granted the Regenerative Medicine Advanced Therapy (RMAT) designation to MiMedx’s AmnioFix Injectable for use in the treatment of osteoarthritis (OA) of the knee.
 

– In 2017, Organogenesis acquired NuTech to support the firm’s development of next-generation amniotic products. The newly-combined company offers a portfolio of advanced next-generation products for the wound care and surgical biologics markets.
 

Browse 101 market data tables and 29 figures spread through 126 pages and in-depth TOC – Request Research Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=191575976
 

Leading Key Players in the Worldwide Industry:
 

The prominent players operating in Amniotic Products Market include MiMedx (US), Smith & Nephew (UK), Organogenesis (US), Integra LifeSciences Corporation (US), Stryker Corporation (US), Wright Medical (Netherlands), Applied Biologics (US), Celularity (US), Katena Products (US), Lucina BioSciences (US), Next Biosciences (South Africa), Skye Biologics (US), Surgenex (US), TissueTech (US), Ventris Medical (US), StimLabs (US), VIVEX Biologics (US), LifeCell International (India), NuVision Biotherapies (England), and Genesis Biologics (US).
 

Geographical Regions Mapped in Report:
 

The Amniotic Membranes Market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. In 2019, North America was the largest market, followed by Europe. This can be attributed to the high prevalence of target diseases, increasing geriatric population, rising awareness about advanced treatment options, and the strong presence of key market players of amniotic products in this region. The presence of a well-established healthcare system and ongoing investments by hospitals to upgrade & expand their operating capabilities are other factors supporting market growth in North America.
 

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=191575976
 

Market Segmentation in Detailed:
 

Based on application, the amniotic products market is categorized into wound care, ophthalmology, orthopedics, and other applications. Wound care was the largest application segment in the market in 2019 and is expected to grow at the highest CAGR during the forecast period. Growth in this market is largely driven by the rising prevalence of diabetic foot ulcers, venous leg ulcers, surgical & traumatic wounds, and burn injuries.
 

On the basis of end user, the Amniotic Membranes Market is segmented into hospitals & ASCs and other end users. In 2019, hospitals & ASCs accounted for the largest share of the amniotic products market and are expected to register the highest CAGR. Growth in this segment can primarily be attributed to factors such as the high demand for wound care biologics (including amniotic tissue products) in hospitals and ASCs, the high patient inflow in this care setting, and the availability of reimbursements